Suppliers and packagers for generic pharmaceutical drug: CHLOROQUINE PHOSPHATE

CHLOROQUINE PHOSPHATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Impax Labs	CHLOROQUINE PHOSPHATE	chloroquine phosphate	TABLET;ORAL	080880	ANDA	Amneal Pharmaceuticals of New York LLC	0115-2790-02	500 TABLET in 1 BOTTLE (0115-2790-02)	2022-05-10
Impax Labs	CHLOROQUINE PHOSPHATE	chloroquine phosphate	TABLET;ORAL	080880	ANDA	Amneal Pharmaceuticals of New York LLC	0115-2790-06	50 TABLET in 1 BOTTLE (0115-2790-06)	2022-05-10
Impax Labs	CHLOROQUINE PHOSPHATE	chloroquine phosphate	TABLET;ORAL	040516	ANDA	Amneal Pharmaceuticals of New York LLC	0115-7010-01	100 TABLET in 1 BOTTLE (0115-7010-01)	2022-05-10
Impax Labs	CHLOROQUINE PHOSPHATE	chloroquine phosphate	TABLET;ORAL	040516	ANDA	Amneal Pharmaceuticals of New York LLC	0115-7010-02	500 TABLET in 1 BOTTLE (0115-7010-02)	2022-05-10
Impax Labs	CHLOROQUINE PHOSPHATE	chloroquine phosphate	TABLET;ORAL	040516	ANDA	Amneal Pharmaceuticals of New York LLC	0115-7010-09	25 TABLET in 1 BOTTLE (0115-7010-09)	2022-05-10
Impax Labs	CHLOROQUINE PHOSPHATE	chloroquine phosphate	TABLET;ORAL	040516	ANDA	AvKARE	42291-047-25	25 TABLET in 1 BOTTLE (42291-047-25)	2023-11-15

Chloroquine Phosphate Suppliers: Manufacturing Landscape and Market Dynamics

Last updated: February 19, 2026

This report analyzes the global supply chain for chloroquine phosphate, identifying key manufacturers, production capacities, regulatory considerations, and market trends. Chloroquine phosphate, an antimalarial and autoimmune disease treatment, faces competition from newer therapies but maintains a consistent demand in specific therapeutic areas and geographic regions.

Who Are the Primary Manufacturers of Chloroquine Phosphate?

The production of chloroquine phosphate is concentrated among a limited number of global chemical and pharmaceutical manufacturers. These entities range from large, diversified chemical companies to specialized active pharmaceutical ingredient (API) producers.

• Key Manufacturers Identified:
  • Sanofi: While historically a major producer, Sanofi's current role in direct chloroquine phosphate API manufacturing requires verification based on ongoing portfolio divestments and strategic shifts. The company previously held significant market share.
  • Bayer AG: Bayer has been a historical producer, though current API manufacturing volume needs specific confirmation.
  • AnkeBio Co., Ltd. (China): This company is a documented supplier of chloroquine phosphate API, serving both domestic and international markets.
  • Jiangxi HEC Pharmaceutical Co., Ltd. (China): Another significant Chinese API producer with chloroquine phosphate in its portfolio.
  • Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (China): This firm is listed as a manufacturer and supplier of chloroquine phosphate.
  • Other Chinese Manufacturers: Numerous smaller and medium-sized Chinese chemical synthesis companies contribute to the global supply. These often operate on a contract manufacturing basis or supply intermediates.
  • Indian Manufacturers: Several Indian API producers also manufacture chloroquine phosphate, catering to the significant pharmaceutical industry in India and export markets. Specific company names require detailed market intelligence surveys.

The geographic concentration of API manufacturing, particularly for older generic drugs like chloroquine phosphate, has increasingly shifted towards Asia, primarily China and India, due to cost efficiencies and established chemical synthesis infrastructure.

What is the Current Production Capacity and Scalability?

Estimating precise, real-time production capacity for chloroquine phosphate API is challenging due to the proprietary nature of manufacturing data. However, industry analysis indicates sufficient existing capacity to meet current global demand.

• Capacity Considerations:
  • Existing Infrastructure: Manufacturers producing chloroquine phosphate often utilize multi-purpose chemical synthesis plants. This allows for flexibility in production based on market demand for various APIs.
  • Scalability: While current demand does not necessitate peak production, the infrastructure is generally scalable. A significant surge in demand, as briefly observed during the early COVID-19 pandemic, would require lead times for raw material procurement and potential adjustments in production scheduling.
  • Raw Material Dependency: The scalability of chloroquine phosphate production is directly linked to the availability and cost of key precursor chemicals. Suppliers of these intermediates, often basic organic chemicals, can become bottlenecks.
  • Regulatory Hurdles for New Capacity: Establishing new API manufacturing facilities or significantly expanding existing ones involves extensive regulatory approval processes, including Good Manufacturing Practices (GMP) compliance and site inspections by health authorities. This limits rapid capacity increases.

Industry reports suggest that global chloroquine phosphate API production capacity is measured in the metric tons per year, with a buffer to accommodate fluctuations.

What are the Key Regulatory Requirements for Chloroquine Phosphate Production?

The manufacturing of chloroquine phosphate API and its finished dosage forms is subject to stringent regulatory oversight by health authorities worldwide. Compliance ensures product safety, efficacy, and quality.

• Primary Regulatory Bodies:

  • U.S. Food and Drug Administration (FDA): Oversees drug manufacturing and approval in the United States. Manufacturers supplying the U.S. market must adhere to FDA's Current Good Manufacturing Practices (cGMP).
  • European Medicines Agency (EMA): Regulates pharmaceuticals in the European Union. Manufacturers require EU GMP certification.
  • Pharmaceuticals and Medical Devices Agency (PMDA) of Japan: The regulatory authority for drugs in Japan.
  • National Medical Products Administration (NMPA) of China: Oversees drug regulation within China.
  • Central Drugs Standard Control Organization (CDSCO) of India: The national regulatory body for pharmaceuticals in India.

• Key Compliance Areas:

  • Good Manufacturing Practices (GMP): This is the cornerstone of pharmaceutical manufacturing. It covers all aspects of production, from raw materials, premises, and equipment to the training and personal hygiene of staff. Specific GMP guidelines are detailed in publications like ICH Q7 for APIs.
  • Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers submit these confidential documents to regulatory agencies detailing the chemistry, manufacturing, and controls (CMC) of the drug substance. This allows drug product manufacturers to reference the API information without full disclosure of the API supplier's proprietary processes.
  • Site Inspections: Regulatory agencies conduct periodic inspections of manufacturing facilities to ensure ongoing compliance with GMP.
  • Quality Control and Assurance: Robust quality control (QC) testing of raw materials, intermediates, and the final API is mandatory. Quality assurance (QA) systems must be in place to oversee all operations.
  • Impurity Profiling: Manufacturers must identify and control impurities within acceptable limits as defined by pharmacopoeias (e.g., USP, EP, JP) and regulatory guidelines.
  • Stability Studies: Data demonstrating the stability of the API under specified storage conditions over time is required.
  • Supply Chain Security: Ensuring the integrity of the supply chain from raw materials to finished product is critical, including measures against counterfeiting and adulteration.

Manufacturers intending to supply to regulated markets must obtain and maintain the necessary certifications and approvals from the respective health authorities.

What is the Market Landscape and Demand for Chloroquine Phosphate?

The market for chloroquine phosphate is characterized by stable, albeit mature, demand, primarily driven by its established therapeutic uses. While it has been superseded by more effective or better-tolerated drugs in some primary indications, it retains a significant role.

• Primary Indications and Demand Drivers:

  • Malaria Treatment and Prophylaxis: Chloroquine phosphate remains a recommended treatment for certain types of malaria, particularly in regions where drug resistance to other antimalarials is not widespread. It is also used for prophylaxis in specific travel scenarios. Demand in sub-Saharan Africa and parts of Southeast Asia contributes to this segment.
  • Autoimmune Diseases: Chloroquine phosphate is used in the treatment of rheumatoid arthritis, lupus erythematosus, and discoid lupus. While newer biologics and targeted therapies exist, chloroquine phosphate remains a cost-effective option for some patients, particularly in resource-limited settings.
  • Other Uses: It has been explored for other off-label uses, but these do not represent significant market drivers compared to its approved indications.

• Market Dynamics:

  • Generic Drug Status: Chloroquine phosphate is a well-established generic drug, meaning its market is highly price-sensitive. Competition among API suppliers is intense.
  • Competition from Newer Therapies: In the malaria space, artemisinin-based combination therapies (ACTs) have become the first-line treatment in many regions due to widespread resistance to older drugs like chloroquine. For autoimmune diseases, newer disease-modifying antirheumatic drugs (DMARDs) and biologics offer different efficacy and safety profiles.
  • Geographic Demand: Demand is geographically segmented. Regions with a high prevalence of chloroquine-sensitive malaria and countries with public health programs supporting its use drive significant volumes. Developed markets primarily utilize it for autoimmune conditions where cost-effectiveness is a factor.
  • COVID-19 Impact: During the early stages of the COVID-19 pandemic, there was a significant but temporary surge in interest and demand for chloroquine phosphate. However, clinical trials did not support its efficacy for COVID-19 treatment, leading to a retraction of this demand.
  • Supply Chain Vulnerabilities: As with many generic APIs, the supply chain can be vulnerable to disruptions, such as geopolitical events, trade restrictions, or quality control issues at key manufacturing sites.

The overall market size for chloroquine phosphate API is stable, with growth being modest and largely dependent on public health initiatives for malaria control and the cost-effectiveness considerations in autoimmune disease management.

What are the Raw Material Requirements and Sourcing Challenges?

The synthesis of chloroquine phosphate involves several chemical intermediates. The availability and consistent quality of these raw materials are critical for uninterrupted production.

• Key Precursor Chemicals:

  • 4,7-Dichloroquinoline: This is a core intermediate in the synthesis of chloroquine. Its production requires specific chemical processes and raw materials.
  • Diethylamine: A common amine used in the synthesis.
  • Other Reagents: Various acids, bases, solvents, and catalysts are required for different steps of the synthesis. Examples include ethanol, hydrochloric acid, and sodium hydroxide.

• Sourcing Challenges:

  • Geographic Concentration of Precursors: Similar to API manufacturing, the production of key chemical intermediates is also concentrated in specific regions, notably China and India. Disruptions in these regions can impact the global supply of chloroquine phosphate.
  • Price Volatility: The prices of basic organic chemicals can fluctuate based on global petrochemical prices, supply-demand dynamics, and regulatory changes affecting their production (e.g., environmental regulations).
  • Quality Consistency: Ensuring the consistent quality and purity of incoming raw materials is paramount. Variations can lead to product quality issues in the final API, requiring extensive re-validation of manufacturing processes.
  • Supplier Qualification: API manufacturers must rigorously qualify their raw material suppliers through audits, sample testing, and quality agreements to ensure reliability and compliance.
  • Lead Times: Sourcing specialized intermediates can involve significant lead times, particularly if there are limited global suppliers or if production is on a campaign basis.

Robust supply chain management, including dual sourcing strategies where feasible and strong relationships with key intermediate suppliers, is essential for chloroquine phosphate manufacturers.

What are the Competitive Dynamics Among Suppliers?

The competitive landscape for chloroquine phosphate API is characterized by a focus on price, quality assurance, and reliable supply.

• Key Competitive Factors:

  • Price: As a mature generic product, price is a primary differentiator. Manufacturers with lower production costs due to economies of scale, efficient processes, or favorable raw material sourcing can offer more competitive pricing.
  • Quality and Regulatory Compliance: Suppliers must consistently meet stringent GMP standards and have a clean regulatory history. A history of FDA 483 observations or warning letters can significantly impair a supplier's competitiveness.
  • Reliability of Supply: The ability to consistently deliver product on time and in the required quantities is crucial. Disruptions in supply can lead pharmaceutical companies to seek alternative, more reliable sources.
  • Technical Support and Documentation: Providing comprehensive technical support, including detailed Certificates of Analysis (CoA), residual solvent data, and assistance with DMF/ASMF filings, is important for customer relationships.
  • Production Volume and Capacity: Larger-scale manufacturers can often command lower per-unit costs and offer greater assurance of supply for bulk orders.
  • Geographic Reach: Suppliers with established distribution networks and experience navigating international shipping and customs regulations have an advantage.

• Market Entry and Exit:

  • Barriers to Entry: Significant barriers exist for new entrants, including the capital investment required for GMP-compliant facilities, the cost and time involved in obtaining regulatory approvals, and the challenge of establishing a competitive price point against established players.
  • Market Exit: Manufacturers may exit the market due to unprofitability driven by price erosion, increasing compliance costs, or strategic decisions to focus on higher-margin products.

The market is generally stable, with established players maintaining their positions through a combination of cost-effectiveness and robust quality systems. Significant shifts are unlikely unless driven by major regulatory changes or disruptions in raw material supply.

Key Takeaways

• Global chloroquine phosphate API manufacturing is concentrated in China and India, with established players focusing on cost-efficiency and GMP compliance.
• Existing production capacity is sufficient to meet current demand, with scalability possible but subject to raw material availability and regulatory timelines.
• Strict adherence to cGMP, robust quality control, and comprehensive regulatory filings (DMF/ASMF) are non-negotiable for market access in regulated geographies.
• The market is mature and price-sensitive, driven by malaria treatment in endemic regions and cost-effective management of autoimmune diseases.
• Sourcing of key chemical intermediates can present challenges due to geographic concentration and price volatility.
• Competition centers on price, consistent quality, and supply chain reliability.

Frequently Asked Questions

1. Which regions are the largest consumers of chloroquine phosphate? The largest consumers are regions with a high prevalence of chloroquine-sensitive malaria, primarily in sub-Saharan Africa and parts of Southeast Asia. Developed countries utilize it for autoimmune disease management.

2. Has the demand for chloroquine phosphate changed significantly in recent years? Demand has been stable for its primary indications. A temporary surge occurred during the early COVID-19 pandemic, but this demand did not persist as clinical evidence did not support its use.

3. What are the main challenges in ensuring a consistent supply of chloroquine phosphate? Challenges include the geographic concentration of both API and intermediate manufacturers, potential price volatility of raw materials, and the stringent regulatory compliance required for manufacturing.

4. Are there significant differences in the quality of chloroquine phosphate API from different manufacturers? Quality differences primarily manifest in purity profiles, impurity levels, and adherence to pharmacopoeial standards. Manufacturers with robust quality management systems and strict adherence to cGMP generally offer higher and more consistent quality.

5. What is the typical shelf life of chloroquine phosphate API? The typical shelf life for chloroquine phosphate API, when stored under recommended conditions (protected from light and moisture), is generally between two to five years, as determined by stability studies conducted by the manufacturer.

Citations

[1] World Health Organization. (2023). Guidelines for the treatment of malaria. Retrieved from https://www.who.int/publications/i/item/9789240075445

[2] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2000). ICH Harmonised Tripartite Guideline Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Retrieved from https://www.ich.org/page/quality-guidelines

[3] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations

[4] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-development/good-manufacturing-practice-compliance

[5] Market research reports on generic APIs and antimalarial drugs (specific report titles and publishers vary and are typically proprietary).